This study is carried out by Prof. Qiang Liu (Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University). In this study, researchers found that the palbociclib-resistant breast cancer ...
Characterization of OASEP1 as a biomarker and therapeutic target for oral cancer. Impact on U251 glioma cell radiosensitivity and CFL1 level via inhibiting cell motility regulator ROCKII of ...
Learning from every patient: Real-world clinical outcomes of patients with metastatic triple-negative breast cancer treated in the community oncology setting.
[button url="http://chem.colorado.edu/" color="blue"]Department of Chemistry and Biochemistry[/button] [button url="www.colorado.edu" color="blue"]University of ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results